Biopharmaceuticals

17th Annual Report and Survey on Biopharmaceutical Manufacturing Capacity and Production - Present and Future Challenges - ResearchAndMarkets.com

Retrieved on: 
Friday, July 24, 2020

The "17th Annual Report and Survey on Biopharmaceutical Manufacturing Capacity and Production" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "17th Annual Report and Survey on Biopharmaceutical Manufacturing Capacity and Production" report has been added to ResearchAndMarkets.com's offering.
  • The 2020 17th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production is the most recent study of biotherapeutic developers and contract manufacturing organizations' current and projected future capacity and production.
  • In-depth analysis and summary of the key survey findings, trends and implications for industry-wide biomanufacturing capacity and biotherapeutic production.
  • Trend analysis in this 17th in a series of annual biopharmaceutical manufacturing industry evaluations.

Optime Care Highlights Role of Telehealth to Maximize Therapeutic Opportunities for Patients with Orphan and Ultra-Orphan Disorders During COVID-19 Pandemic and Beyond

Retrieved on: 
Monday, July 20, 2020

In partnership with Optime Care, specialty drug manufacturers better serve patients, caregivers, providers and payers to help them overcome key challenges around the complexity of these conditions.

Key Points: 
  • In partnership with Optime Care, specialty drug manufacturers better serve patients, caregivers, providers and payers to help them overcome key challenges around the complexity of these conditions.
  • The net result is that patients have a better experience a critical component of a products value and gain stronger compliance outcomes.
  • Optime Care, Inc. is a nationally recognized pharmacy, distribution and patient management organization offering a suite of comprehensive services tailored to maximize the therapeutic opportunities for the treatment of orphan and rare disorders.
  • Our experience with small patient populations makes us uniquely qualified to help every stakeholder group impacted by these disorders.

BioLife Solutions evo® Cold Chain Management Platform Now Supporting Over 100 Early Stage Cell & Gene Therapy Clinical Trials

Retrieved on: 
Wednesday, July 15, 2020

Via its relationships with leading specialty couriers World Courier and Quick International Courier, the evo platform is used to transport and monitor shipments of source material and manufactured doses in more than 100 cell and gene therapy clinical trials.

Key Points: 
  • Via its relationships with leading specialty couriers World Courier and Quick International Courier, the evo platform is used to transport and monitor shipments of source material and manufactured doses in more than 100 cell and gene therapy clinical trials.
  • Their combined worldwide footprint enables our evo platform to support clinical trials of novel cell and gene therapies in all major markets.
  • The founders of SAVSU brought class-defining cold chain management solutions to this space with BioLife's insistence on quality by design and best practices.
  • For more information, please visit www.quick.aero
    BioLife Solutions is a leading supplier of cell and gene therapy bioproduction tools.

BioLife Solutions Announces $9.6 Million to $9.8 Million in Preliminary Revenue for Q2 2020

Retrieved on: 
Wednesday, July 1, 2020

In the first six months of 2020, we added 57 new customers and confirmed that our biopreservation media products have been embedded in 23 additional customer clinical trials."

Key Points: 
  • In the first six months of 2020, we added 57 new customers and confirmed that our biopreservation media products have been embedded in 23 additional customer clinical trials."
  • BioLife Solutions is a leading supplier of cell and gene therapy bioproduction tools.
  • Except for historical information contained herein, this press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
  • All statements other than statements of historical fact are statements that could be deemed forward-looking statements.

Avid Bioservices Names Nicholas Green as President and Chief Executive Officer

Retrieved on: 
Tuesday, June 23, 2020

Joseph Carleone, Ph.D., chairman of the Avid board of directors, said, On behalf of the Avid board, Id like to welcome Nick as our new president and CEO.

Key Points: 
  • Joseph Carleone, Ph.D., chairman of the Avid board of directors, said, On behalf of the Avid board, Id like to welcome Nick as our new president and CEO.
  • His appointment is the result of a deliberate and comprehensive search for an industry executive capable of leading Avid to achieve its full potential.
  • I am excited to join the Avid team and contribute my industry experience to helping the company continue its impressive growth trajectory, said Mr. Green.
  • Mr. Green most recently served as president and CEO of Therapure Biopharma, a Canada-based biopharmaceutical company which includes Therapure Biomanufacturing.

Premier Inc. Creates Oncology-Focused Purchasing Alliance with 20 Leading Cancer Providers to Source Branded Cancer Drugs

Retrieved on: 
Thursday, June 18, 2020

Premier Inc. (NASDAQ: PINC), a leading healthcare improvement company, today debuted Intersectta, a new oncology-focused group purchasing organization (GPO) to source cancer and other specialty drugs.

Key Points: 
  • Premier Inc. (NASDAQ: PINC), a leading healthcare improvement company, today debuted Intersectta, a new oncology-focused group purchasing organization (GPO) to source cancer and other specialty drugs.
  • Through this program, Premier plans to strike innovative new partnerships with pharmaceutical companies, putting branded products on negotiated contracts at competitive prices.
  • In addition, Premier will provide participants access to robust market data to better understand real-world prescribing, utilization and off-label trends.
  • Premier Inc. (NASDAQ: PINC) is a leading healthcare improvement company, uniting an alliance of more than 4,000 U.S. hospitals and health systems and approximately 175,000 other providers and organizations to transform healthcare.

Codexis Announces the Election of New Directors at its Annual Meeting of Stockholders

Retrieved on: 
Tuesday, June 16, 2020

Dr. Moore brings to Codexis significant experience as a biotechnology and pharmaceutical executive, including an extensive background in biomanufacturing.

Key Points: 
  • Dr. Moore brings to Codexis significant experience as a biotechnology and pharmaceutical executive, including an extensive background in biomanufacturing.
  • Dr. Moore holds a bachelors degree in Pharmacology with Honors and a Ph.D. in Cell Biology from Manchester University, England.
  • Moore and Dilly, Codexis stockholders also re-elected Dr. Patrick Yang earlier today to continue to serve on the board.
  • Codexis expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.

COVIDPulse Allows Pharma Companies to Compare Pre-COVID Physician and Patient Treatment, Prescribing, and Compliance Behaviors to Current Behaviors

Retrieved on: 
Tuesday, June 16, 2020

Now more than ever, life sciences companies need to understand how COVID-19 has affected healthcare providers, physician practices and patients, said Dave Fitzhenry, CEO, Trinity Life Sciences.

Key Points: 
  • Now more than ever, life sciences companies need to understand how COVID-19 has affected healthcare providers, physician practices and patients, said Dave Fitzhenry, CEO, Trinity Life Sciences.
  • COVIDPulse allows pharma companies to assess how physicians are coping with treating patients during the pandemic and how they, as the manufacturer of critical drugs and treatments, need to provide support.
  • Designed to measure by physician specialty, product and indication, the key questions COVIDPulse answers include:
    What impact has the pandemic had on patient volume?
  • COVIDPulse can be used as a snapshot or on an ongoing basis to monitor shift over time to support decision-making.

NIIMBL Announces $10M in New Project Funding Towards Advances in Biopharmaceutical Manufacturing Innovation

Retrieved on: 
Tuesday, May 19, 2020

As a result of these new Project Call 3.1 projects, NIIMBL is bolstering their technology portfolio to include critical areas such as process analytical technologies for contaminant detection, cell therapy manufacturing processes, single-use components for continuous manufacturing, and data analytics applications in biomanufacturing.

Key Points: 
  • As a result of these new Project Call 3.1 projects, NIIMBL is bolstering their technology portfolio to include critical areas such as process analytical technologies for contaminant detection, cell therapy manufacturing processes, single-use components for continuous manufacturing, and data analytics applications in biomanufacturing.
  • "The demands on the biopharmaceutical industry have grown exponentially over the last few months as our world is facing unprecedented times.
  • For a description of each project and to learn more about NIIMBL, please visit NIIMBL.org .
  • The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) is a public-private partnership whose mission is to accelerate biopharmaceutical innovation, support the development of standards that enable more efficient and rapid manufacturing capabilities, and educate and train a world-leading biopharmaceutical manufacturing workforce, fundamentally advancing U.S. competitiveness in this industry.

BioLife Solutions Promotes Marcus Schulz to Vice President, Global Sales

Retrieved on: 
Monday, May 18, 2020

BOTHELL, Wash., May 18, 2020 /PRNewswire/ -- BioLife Solutions , Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of best-in-class bioproduction tools for cell and gene therapies, today announced the promotion of Marcus Schulz to the position of Vice President, Global Sales.

Key Points: 
  • BOTHELL, Wash., May 18, 2020 /PRNewswire/ -- BioLife Solutions , Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of best-in-class bioproduction tools for cell and gene therapies, today announced the promotion of Marcus Schulz to the position of Vice President, Global Sales.
  • Schulz joined BioLife Solutions in August 2019 as Vice President of Sales, evo Platform.
  • Mike Rice, Chief Executive Officer, commented, "Marcus is a dynamic, driven, and creative senior sales leader.
  • "On behalf of the entire BioLife team, I also want to recognize the significant contributions Jim Mathers made in building BioLife Solutions.